Streetbeat News

FRLN

Freeline Therapeutics Holdings plc

https://www.freeline.life/

Employees

717

Industry

Biological Product (except Diagnostic) Manufacturing

freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation aav gene therapy platform developed by amit nathwani, professor of haematology at ucl and cso of freeline therapeutics http://www.freelinetx.com

Open

6.49

Mkt cap

28M

Volume

5.3K

High

6.49

P/E Ratio

-0.57

52-wk high

8.74

Low

6.48

Div yield

N/A

52-wk low

2.11

HC Wainwright & Co. analyst Patrick Trucchio has downgraded Freeline Therapeutics (NASDAQ:FRLN) from Buy to Neutral and reduced the price target from $15 to $6.5.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:10 pm

Freeline Therapeutics' stock is trading higher following the announcement of a definitive agreement for its acquisition by Syncona.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 4:42 pm

Syncona Ltd has agreed to acquire Freeline Therapeutics Holdings plc (NASDAQ:FRLN) for approximately $28.3 million, or $6.50 per ADS, a 51% premium over the pre-announcement closing price. The acquisition is expected to close in Q1 2024, and Freeline will become a wholly owned Syncona portfolio company, delisting from Nasdaq. Syncona will also provide up to $15 million in convertible debt financing to support Freeline's operations and FLT201 development. Freeline's shares rose 11.3% to $6.43 after the announcement.

Portfolio Pulse from Vandana Singh

November 22, 2023 | 2:49 pm

Freeline Therapeutics ADS shares are set to resume trading at 8:00 A.M. ET after a halt.

Portfolio Pulse from Charles Gross

November 22, 2023 | 12:38 pm

Syncona, a healthcare company focused on founding, building, and funding global leaders in life science, has agreed to acquire Freeline Therapeutics for $28.3 million. Freeline Therapeutics, which may be referred to by its ticker FRLN, is a biotechnology firm specializing in gene therapies.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 12:36 pm

Trading in Freeline Therapeutics Holdings (FRLN) has been halted pending the release of material news from the company. Investors are awaiting the announcement, which could significantly impact the stock's performance.

Portfolio Pulse from Charles Gross

November 22, 2023 | 12:25 pm

Freeline has presented new data from its Phase 1/2 GALILEO-1 trial of FLT201, a novel gene therapy candidate for Gaucher disease. The results are promising and could potentially lead to a new treatment option for patients with this rare genetic disorder.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 7:27 am

Freeline Therapeutics (NASDAQ:FRLN) has received 2 bullish and 2 indifferent ratings from analysts in the last quarter. The company's average price target has increased by 77.27% over the past month, with a current average of $9.75, a high of $15.00, and a low of $4.00.

Portfolio Pulse from Benzinga Insights

October 18, 2023 | 9:00 pm

The article lists the stocks that have gained and lost the most in Wednesday's mid-day session. Notable gainers include Shift Technologies, Treasure Global, and SeaStar Medical Holding, while significant losers include Nuvve Holding, NuZee, and Color Star Technology. Factors influencing these changes range from bankruptcy filings and FDA approvals to public offerings and earnings reports.

Portfolio Pulse from Lisa Levin

October 18, 2023 | 6:15 pm

Wedbush analyst David Nierengarten has downgraded Freeline Therapeutics (NASDAQ:FRLN) from Outperform to Neutral and lowered the price target from $8 to $5.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 2:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.